# Safety, Tolerability and Pharmacokinetics of Liraglutide-depot in Healthy Subjects

> **NCT01473953** · PHASE1 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 31 (actual)

## Conditions studied

- Diabetes
- Diabetes Mellitus, Type 2
- Healthy

## Interventions

- **DRUG:** liraglutide-depot
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT01473953
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-10
- **Primary completion:** 2012-03
- **Final completion:** 2012-03
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2017-03-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01473953

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01473953, "Safety, Tolerability and Pharmacokinetics of Liraglutide-depot in Healthy Subjects". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01473953. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*